What is Alumis Inc.'s deferred revenue?

Alumis Inc. (ALMS) reported deferred revenue of $6.33M in Q1 2026.

What does deferred revenue mean?

Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.

Alumis Inc. ALMS Deferred Revenue

Deferred Revenue at other companies

ImmunomeIMNM

$0-100%

Aurinia PharmaceuticalsAUPH

$5.04M+9.6%

Dianthus TherapeuticsDNTH

$6.32M+242%

Protagonist TherapeuticsPTGX

$6.28M-23.2%

Kymera TherapeuticsKYMR

$0-100%

Adaptive BiotechnologiesADPT

$49.4M-9.9%

Other financials

Income statement

See full

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

See full

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

See full

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation

See full

Market cap$3.17B+739%

Profitability

See full

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

See full

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alumis Inc.'s deferred revenue?: Alumis Inc. (ALMS) reported deferred revenue of $6.33M in Q1 2026.
What does deferred revenue mean?: Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.